Hypertension - Pipeline Review, H1 2016
Summary
Global Markets Direct’s, ‘Hypertension - Pipeline Review, H1 2016’, provides an overview of the Hypertension pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hypertension
- The report reviews pipeline therapeutics for Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hypertension
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
Introduction 8
Hypertension Overview 9
Therapeutics Development 10
Hypertension - Therapeutics under Development by Companies 12
Hypertension - Therapeutics under Investigation by Universities/Institutes 21
Hypertension - Pipeline Products Glance 23
Hypertension - Products under Development by Companies 26
Hypertension - Products under Investigation by Universities/Institutes 39
Hypertension - Companies Involved in Therapeutics Development 41
Hypertension - Therapeutics Assessment 141
Drug Profiles 161
Hypertension - Recent Pipeline Updates 420
Hypertension - Dormant Projects 506
Hypertension - Discontinued Products 530
Hypertension - Product Development Milestones 533
Appendix 541
List Of Tables
List of Tables
Number of Products under Development for Hypertension, H1 2016 32
Number of Products under Development for Hypertension - Comparative Analysis, H1 2016 33
Number of Products under Development by Companies, H1 2016 35
Number of Products under Development by Companies, H1 2016 (Contd..1) 36
Number of Products under Development by Companies, H1 2016 (Contd..2) 37
Number of Products under Development by Companies, H1 2016 (Contd..3) 38
Number of Products under Development by Companies, H1 2016 (Contd..4) 39
Number of Products under Development by Companies, H1 2016 (Contd..5) 40
Number of Products under Development by Companies, H1 2016 (Contd..6) 41
Number of Products under Development by Companies, H1 2016 (Contd..7) 42
Number of Products under Investigation by Universities/Institutes, H1 2016 44
Comparative Analysis by Late Stage Development, H1 2016 45
Comparative Analysis by Clinical Stage Development, H1 2016 46
Comparative Analysis by Early Stage Development, H1 2016 47
Products under Development by Companies, H1 2016 48
Products under Development by Companies, H1 2016 (Contd..1) 49
Products under Development by Companies, H1 2016 (Contd..2) 50
Products under Development by Companies, H1 2016 (Contd..3) 51
Products under Development by Companies, H1 2016 (Contd..4) 52
Products under Development by Companies, H1 2016 (Contd..5) 53
Products under Development by Companies, H1 2016 (Contd..6) 54
Products under Development by Companies, H1 2016 (Contd..7) 55
Products under Development by Companies, H1 2016 (Contd..8) 56
Products under Development by Companies, H1 2016 (Contd..9) 57
Products under Development by Companies, H1 2016 (Contd..10) 58
Products under Development by Companies, H1 2016 (Contd..11) 59
Products under Development by Companies, H1 2016 (Contd..12) 60
Products under Investigation by Universities/Institutes, H1 2016 61
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 62
Hypertension - Pipeline by A1M Pharma AB, H1 2016 63
Hypertension - Pipeline by AbbVie Inc., H1 2016 64
Hypertension - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 65
Hypertension - Pipeline by Actelion Ltd, H1 2016 66
Hypertension - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016 67
Hypertension - Pipeline by Allergan Plc, H1 2016 68
Hypertension - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 69
Hypertension - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 70
Hypertension - Pipeline by APT Therapeutics, Inc., H1 2016 71
Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 72
Hypertension - Pipeline by Ascendis Pharma A/S, H1 2016 73
Hypertension - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 74
Hypertension - Pipeline by Bayer AG, H1 2016 75
Hypertension - Pipeline by Bial - Portela & Ca, S.A., H1 2016 76
Hypertension - Pipeline by Bio-inRen, H1 2016 77
Hypertension - Pipeline by BioRestorative Therapies, Inc., H1 2016 78
Hypertension - Pipeline by Bristol-Myers Squibb Company, H1 2016 79
Hypertension - Pipeline by Cellceutix Corporation, H1 2016 80
Hypertension - Pipeline by Celsion Corporation, H1 2016 81
Hypertension - Pipeline by Celtaxsys, Inc., H1 2016 82
Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 83
Hypertension - Pipeline by CJ HealthCare Corp., H1 2016 84
Hypertension - Pipeline by Complexa, Inc., H1 2016 85
Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H1 2016 86
Hypertension - Pipeline by Cytokinetics, Inc., H1 2016 87
Hypertension - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 88
Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 89
Hypertension - Pipeline by DiaMedica Inc., H1 2016 90
Hypertension - Pipeline by Eli Lilly and Company, H1 2016 91
Hypertension - Pipeline by Esperion Therapeutics, Inc., H1 2016 92
Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 93
Hypertension - Pipeline by Galectin Therapeutics, Inc., H1 2016 94
Hypertension - Pipeline by Genextra S.p.a., H1 2016 95
Hypertension - Pipeline by Gilead Sciences, Inc., H1 2016 96
Hypertension - Pipeline by GlaxoSmithKline Plc, H1 2016 97
Hypertension - Pipeline by Glenveigh Medical, LLC, H1 2016 98
Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 99
Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 100
Hypertension - Pipeline by HitGen LTD, H1 2016 101
Hypertension - Pipeline by Innopharmax Inc., H1 2016 102
Hypertension - Pipeline by Insmed Incorporated, H1 2016 103
Hypertension - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 104
Hypertension - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 105
Hypertension - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 106
Hypertension - Pipeline by Johnson & Johnson, H1 2016 107
Hypertension - Pipeline by JW Pharmaceutical Corporation, H1 2016 108
Hypertension - Pipeline by Kowa Company, Ltd., H1 2016 109
Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 110
Hypertension - Pipeline by Les Laboratoires Servier SAS, H1 2016 111
Hypertension - Pipeline by LFB S.A., H1 2016 112
Hypertension - Pipeline by LG Life Science LTD., H1 2016 113
Hypertension - Pipeline by LinXis B.V., H1 2016 114
Hypertension - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2016 115
Hypertension - Pipeline by Mallinckrodt Plc, H1 2016 116
Hypertension - Pipeline by Mast Therapeutics, Inc., H1 2016 117
Hypertension - Pipeline by Merck & Co., Inc., H1 2016 118
Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H1 2016 119
Hypertension - Pipeline by miRagen Therapeutics, Inc., H1 2016 120
Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 121
Hypertension - Pipeline by Morphogen-IX Limited, H1 2016 122
Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 123
Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H1 2016 124
Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 125
Hypertension - Pipeline by Novartis AG, H1 2016 126
Hypertension - Pipeline by Noxamet Ltd, H1 2016 127
Hypertension - Pipeline by Omeros Corporation, H1 2016 128
Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 129
Hypertension - Pipeline by Peloton Therapeutics, Inc., H1 2016 130
Hypertension - Pipeline by Pfizer Inc., H1 2016 131
Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 132
Hypertension - Pipeline by Pluristem Therapeutics Inc., H1 2016 133
Hypertension - Pipeline by Proteo, Inc., H1 2016 134
Hypertension - Pipeline by Pulmokine, Inc., H1 2016 135
Hypertension - Pipeline by Quantum Genomics SA, H1 2016 136
Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 137
Hypertension - Pipeline by RedHill Biopharma Ltd., H1 2016 138
Hypertension - Pipeline by Respira Therapeutics, Inc., H1 2016 139
Hypertension - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 140
Hypertension - Pipeline by Sanofi, H1 2016 141
Hypertension - Pipeline by Selten Pharma, Inc, H1 2016 142
Hypertension - Pipeline by Serodus ASA, H1 2016 143
Hypertension - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016 144
Hypertension - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 145
Hypertension - Pipeline by Silence Therapeutics Plc, H1 2016 146
Hypertension - Pipeline by Simcere Pharmaceutical Group, H1 2016 147
Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H1 2016 148
Hypertension - Pipeline by Suda Ltd, H1 2016 149
Hypertension - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 150
Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 151
Hypertension - Pipeline by The Medicines Company, H1 2016 152
Hypertension - Pipeline by Theravance Biopharma, Inc., H1 2016 153
Hypertension - Pipeline by Toray Industries, Inc., H1 2016 154
Hypertension - Pipeline by Torrent Pharmaceuticals Limited, H1 2016 155
Hypertension - Pipeline by TSH Biopharm Corporation Limited, H1 2016 156
Hypertension - Pipeline by vasopharm GmbH, H1 2016 157
Hypertension - Pipeline by VBS Pharmaceuticals, H1 2016 158
Hypertension - Pipeline by Vectura Group Plc, H1 2016 159
Hypertension - Pipeline by VG Life Sciences, Inc., H1 2016 160
Hypertension - Pipeline by Vicore Pharma AB, H1 2016 161
Hypertension - Pipeline by Yuhan Corporation, H1 2016 162
Assessment by Monotherapy Products, H1 2016 163
Assessment by Combination Products, H1 2016 164
Number of Products by Stage and Target, H1 2016 166
Number of Products by Stage and Mechanism of Action, H1 2016 174
Number of Products by Stage and Route of Administration, H1 2016 180
Number of Products by Stage and Molecule Type, H1 2016 182
Hypertension Therapeutics - Recent Pipeline Updates, H1 2016 442
Hypertension - Dormant Projects, H1 2016 528
Hypertension - Dormant Projects (Contd..1), H1 2016 529
Hypertension - Dormant Projects (Contd..2), H1 2016 530
Hypertension - Dormant Projects (Contd..3), H1 2016 531
Hypertension - Dormant Projects (Contd..4), H1 2016 532
Hypertension - Dormant Projects (Contd..5), H1 2016 533
Hypertension - Dormant Projects (Contd..6), H1 2016 534
Hypertension - Dormant Projects (Contd..7), H1 2016 535
Hypertension - Dormant Projects (Contd..8), H1 2016 536
Hypertension - Dormant Projects (Contd..9), H1 2016 537
Hypertension - Dormant Projects (Contd..10), H1 2016 538
Hypertension - Dormant Projects (Contd..11), H1 2016 539
Hypertension - Dormant Projects (Contd..12), H1 2016 540
Hypertension - Dormant Projects (Contd..13), H1 2016 541
Hypertension - Dormant Projects (Contd..14), H1 2016 542
Hypertension - Dormant Projects (Contd..15), H1 2016 543
Hypertension - Dormant Projects (Contd..16), H1 2016 544
Hypertension - Dormant Projects (Contd..17), H1 2016 545
Hypertension - Dormant Projects (Contd..18), H1 2016 546
Hypertension - Dormant Projects (Contd..19), H1 2016 547
Hypertension - Dormant Projects (Contd..20), H1 2016 548
Hypertension - Dormant Projects (Contd..21), H1 2016 549
Hypertension - Dormant Projects (Contd..22), H1 2016 550
Hypertension - Dormant Projects (Contd..23), H1 2016 551
Hypertension - Discontinued Products, H1 2016 552
Hypertension - Discontinued Products (Contd..1), H1 2016 553
Hypertension - Discontinued Products (Contd..2), H1 2016 554
Lisst Of Figures
List of Figures
Number of Products under Development for Hypertension, H1 2016 32
Number of Products under Development for Hypertension - Comparative Analysis, H1 2016 33
Number of Products under Development by Companies, H1 2016 34
Number of Products under Investigation by Universities/Institutes, H1 2016 43
Comparative Analysis by Late Stage Development, H1 2016 45
Comparative Analysis by Clinical Stage Development, H1 2016 46
Comparative Analysis by Early Stage Products, H1 2016 47
Assessment by Monotherapy Products, H1 2016 163
Assessment by Combination Products, H1 2016 164
Number of Products by Top 10 Targets, H1 2016 165
Number of Products by Stage and Top 10 Targets, H1 2016 165
Number of Products by Top 10 Mechanism of Actions, H1 2016 173
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 173
Number of Products by Top 10 Routes of Administration, H1 2016 179
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 179
Number of Products by Top 10 Molecule Types, H1 2016 181
Number of Products by Stage and Top 10 Molecule Types, H1 2016 181
